Plasma and serum (A61K35/16)

ethod, test tube and device for making of compositions for wound healing // 2614722
FIELD: medicine; pharmaceuticals.SUBSTANCE: group of inventions relates to pharmaceutics and medicine and concerns method of making composition for healing of wounds and tissues including sampling of whole blood in test tube containing hyaluronic acid without mixing of whole blood and hyaluronic acid, centrifugation of said test tube and collection of supernatant containing said hyaluronic acid and platelet rich plasma. Composition obtained using said methods is used as matrix, cell nutrient medium or medium for implantation of cells and can be used in surgery, dentistry, orthopedics, mesotherapy, as well as in cosmetics and/or esthetics.EFFECT: group of inventions provides immediate use of obtained autologous blood cells with simultaneous preservation of their integrity for wound healing.25 cl, 14 ex, 16 dwg
Combination for acne treatment and method of its application // 2614392
FIELD: pharmacy.SUBSTANCE: combination for acne treatment, comprising an aqueous Gynura Procumbens leaf extract, and means containing non-activated platelets and white blood cells in their own blood plasma. A method of acne treatment by application of the above combination.EFFECT: combination and treatment method are characterized by high efficiency in acne treatment.2 cl, 2 dwg

Treatment method for chronical atrophic pharyngitis // 2613186
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to the medicine, particularly, to the otolaryngology, and may be used for the treatment of the chronical atrophic pharyngitis. For this purpose, an application anesthesia with 2% lidocaine solution is performed, autoplasma containing thrombocytes with the concentration of (351-451)109/l is administered into the submucous membrane of the pharynx, one 0.2-0.3 ml injection to the area of each lateral cushion, and two injections of 0.2-0.3 ml are administered either into each upper part or into each lower part of the pharynx. The procedures with 6 injections are performed in 4-6 days, whereupon, the luminotherapy is additionally conducted with the impact on the oropharynx with an open mouth, and/or on the left and right sides of the neck by the non-coherent, polarized, polychromatic, and low-energy light with the wave-length of 480-3,400 nm, flow density of the light energy per minute of 2.4 J/cm2, the degree of polarization of 95-98% during 10-12 minutes daily with 12-14 days.EFFECT: method of actuation of the regeneration process of the mucous membrane of the pharynx and improvement of microcirculation in tissues without side effects.3 dwg, 2 ex
ethod for treating chronic inflammation of paradentium tissues and mucous membrane with hyperkeratosis in young individuals // 2606040
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to therapeutic dentistry. Proposed method of treating chronic inflammation in case of inflammatory periodontal diseases involves injection of platelet-rich plasma into gingival papilla, marginal part of the gum and transitory fold, wherein said injection is performed at the volume of 0.1–0.5 ml per mm2 – once a week, 2–3 times, Additionally, the placental preparation – "Laennek" – is injected in gingival papilla, marginal part of the gum and transitory fold at the volume of 0.1–0.2 ml per mm2, at 1 injection every 2 days, overall 5–10 injections.EFFECT: use of the invention increases efficiency of local treatment of chronic inflammation in case of inflammatory periodontal diseases – gingivitis and periodontitis, and allows to prolong remission.1 cl, 1 ex

ethod of treating septic shock accompanied with agranulocytosis // 2604672
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to intensive therapy, and can be used for septic shock treating. This is ensured by intravenous introduction of multipotent mesenchymal stem cells derived from the donor's bone marrow, grown on a medium with human blood plasma enriched with lyzed thrombocytes in amount of 1-1.5×106 of the transplanted cells per 1 kg of patient's body weight once in the first 10 hours from the moment of septic shock developing.EFFECT: given method enables to use multipotent mesenchymal stem cells, reducing the intensity of multiple organ failure and thereby improving therapeutic effects of septic shock treatment accompanied with agranulocytosis.1 cl, 3 ex, 2 dwg
ethod for esthetic remodelling of involutional changes of facial skin // 2603618
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to physiotherapy and dermatocosmetology, and can be used for esthetic remodelling of involutional changes of facial skin. Single-step infrared low-intensity laser radiation and platelet rich blood plasma impacts are applied. Intervention is performed in two stages: at the first stage patient's venous blood sampling is performed in the volume of 20-40 ml, and it is centrifuged at 4,000 rpm for 5 minutes to obtain the fraction of platelet-rich plasma. At the second stage plasma is applied on facial skin and without time interval infrared low-intensity laser radiation impact with the wave length of 0.89 microns is applied. Pulse repetition frequency is from 80 to 1,500 Hz - mode of constantly varying frequency. Pulse power is 4-6 W/pulse. Contact-labile technique, 1-3 minutes per a field. Total exposure time is up to 10 minutes. For the therapeutic course of 10 procedures 2 times a week.EFFECT: method provides increase in effectiveness of involutional changes reduction of facial skin, improves quality characteristics of skin, ensure decrease of hyperpigmentation and elimination of telangiectasia by trophic and regenerative effects, normalization of water and oxygen metabolism in tissues, increase in production of collagen and elastin by fibroblasts.1 cl, 5 dwg, 2 ex
ethod of treating patients with severe ovary hyperstimulation syndrome // 2603319
FIELD: medicine.SUBSTANCE: invention relates to medicine, specifically to gynaecology. Treatment consists of two stages. First stage is carried out before entry into the therapeutic cycle and involves sampling, freezing and storage of autoplasma, herewith within the period from 12 months to 30 days before entry of the patient into the therapeutic cycle. 3-4 plasmapheresis sessions are performed. After exfusion the blood taken from the median cubital vein is centrifuged in a cold centrifuge. Corpuscles are returned to the patient, and the obtained autoplasma is frozen at the temperature of -40 °C, herewith the volume of the taken blood per one session of plasmapheresis is 250-300 ml in patients with the weight up to 55 kg and 400-500 ml in patients with the weight over 55 kg, with an interval between sessions of not less than 7 days. Second stage is used as per the fact of diagnostics of the ovary hyperstimulation syndrome, previously prepared frozen autoplasma is thawed and its infusion is done not later than 1 hour after the thawing using a sterile infusion system for infusion solutions with a filter for 170-200 mcm and an air valve.EFFECT: method enables preventing developing multiple organ failure by restoring the volume of circulating plasma; elimination of hemoconcentration, electrolyte imbalance, prevention of acute renal insufficiency and thromboembolic complications, reducing the length of treatment of ovary hyperstimulation syndrome and reducing the rate of adverse reactions.1 cl, 5 ex

ethod of treating endothelial epithelial corneal dystrophy // 2601317
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to ophthalmology, and aims at treating endothelial epithelial corneal dystrophy (EECD). Method involves introducing a suspension of autologous blood mononuclear leukocytes into the posterior chamber of the eye until it replaces the aqueous humor in the anterior chamber by performing paracentesis near the corneal limbus. For this purpose, paracentesis is performed twice at 7 and 11 o'clock with the puncture size of 1-2 mm, wherein an irrigation system in the form of a cannula used to supply sterile air at the pressure of up to 0.2 atm into the anterior chamber is installed into one of the punctures; and 96-98 % cell suspension of autologous blood mononuclear leukocytes is syringed once through the second paracentesis into the anterior chamber between the inner surface of the cornea and air bubble. Then the irrigation system is removed and edges of paracenteses are hydrated. Suspension of autologous blood mononuclear leukocytes is obtained by extraction using the density gradient fractionation method and separating solution of Ficoll-verografin.EFFECT: use of the invention enables to reduce the length of treatment and complications associated with excessive involvement of ocular tissues, corneal oedema.1 cl, 10 dwg
ethod of treatment of chronic odontogenic osteomyelitis in drug-addicts patients // 2599874
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to maxillofacial surgery, and can be used during the final stage of operation sequestrectomy in chronic Odontogenic osteomyelitis in drug-addicts patients. Note here that before the operation is prepared thrombocyte enriched blood plasma (PRP-gel), for this purpose native blood is sampled from the patient's vein in a volume of 40-80 ml. Then injected into the blood anticoagulant, then platelet enriched blood plasma by centrifugation. Besides, before the surgery, also prepared blood plasma, rich with thrombocytes with high content of fibrin (FRP-membrane), for this purpose native blood is sampled from the patient's vein in a volume of 40-80 ml, activator is administered in blood, then enrich with platelets by centrifugation. During the operation sequestrectomy injection of PRP-gel in the spongy substance of wound edges of the bone defect jaw is carried out, a bone defect is filled and closed by FRP-membranes. After that provided mobilization and movement of the mucoperiosteal flap with closing the bone defect and the wound is closed tightly.EFFECT: method ensures high efficiency of operation with low traumatism and low cost.6 cl
ethod of treating osgood-schlatter syndrome // 2599202
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to orthopedics, and can be used for the treatment of an Osgood-Shlatter disease. To do this, in the area of the affected apophis from medial, lateral, distal and proximal sides of the tibial tuberosity, as well as from front to back in the region of maximum pain, by injection administer platelet rich autoplasma. Thus autoplasma is obtained in 10-15 minutes before the procedure and is administered in equal portions in a total dose from 2 to 3 ml.EFFECT: method provides a low-trauma intervention, reducing the period of pain relief, acceleration of time of clinical and radiological recovery with no recurrence of the disease due to the effective stimulation of bone tissue regeneration in the knee joint as a result of revascularization, improvement of microcirculation and acceleration of metabolism of the tissues.1 cl, 2 ex

ethod of treatment skin wounds in mammals with the help of thrombocytic auto plasma // 2599126
FIELD: veterinary science.SUBSTANCE: invention refers to treating skin wounds of mammals. Method involves blood sampling in a mammal and preparation of the required volume of thrombocytic auto plasma. Wherein previously carry out the measurement of wound area. For vast wounds with area more than 20 cm2 determination of the injected volume of thrombocytic auto plasma is carried out in the following way: wound diameter is measured in the widest part thereof and prepare volume of thrombocytic auto plasma in ml, which is equal to diameter of the wound in cm. Obtained volume of thrombocytic auto plasma is divided into 4-5 injections, which is carried out at the boundary of the wound surface with the healthy skin. Needle is inserted at a depth of 0.5-1 cm. So the wound is treated with 1 time of 3, 5 or 7 days. Frequency of administration is 3 to 6 times depending on the status of the wound. Administration of thrombocytic auto plasma is terminated after completion of the stage of epithelization.EFFECT: method enables to increase effectivity of wound repair in any type of a mammal, promotes faster healing process, as well as prevention and treatment of purulent process in the wound.1 cl, 5 dwg, 1 ex
ethod of ossiculoplasty // 2597369
FIELD: medicine.SUBSTANCE: invention relates to medicine, particularly to otorhinolaryngology. It takes place the replacement of pathologically altered fragments of auditory ossicles with bioinert transplantate and covering the bottom of the translantate with platelet-rich pieces of autoblood plasma of a patient, sized 2-3 mm. Plasma pieces are strengthened by application of several drops of bioadhesive “Sulphacrylate” with further waiting during 1-2 minutes for bioadhesive to demonstrate its fixative power.EFFECT: method allows simplifying attachment of prosthetic elements, reducing risk of their displacement during postoperative period till formation of physiological fixation by creation simple and efficient biodegradable frame, which holds prosthesis in required position without aggressive impact on the structures of middle and inner ears.1 cl, 1 ex
ethod of conservative treatment of trophic ulcers of soft tissues // 2593582
FIELD: medicine. SUBSTANCE: invention refers to medicine, namely to surgery, and can be used for conservative treatment of patients with trophic ulcers of soft tissues. That is preceded by activation of autoplasma by centrifugation for 5 minutes with subsequent addition of 10 % calcium chloride solution in amount of 1:1. Then mixture is controlled for 20 minutes at temperature of 40 °C to obtain stabilised biologically active film. After treatment of ulcer and adjoining tissue with shock wave 100-1,000 strikes per cm2, with impact strength 0.1 mJ/1 mm2 and treatment of ulcer with sterile neutral solution produced film is applied on ulcer and covered with aseptic dressing. Procedure is repeated 7-8 times every 5 days. EFFECT: method allows achieving healing trophic ulcers, reduced risk of extensive intermuscular hematomas, bleeding wound infections, thromboembolism, does not require hospital patients and anaesthesia care. 1 cl, 1 ex

ethod and apparatus for producing serum with thrombin from one donor // 2589648
FIELD: medicine.SUBSTANCE: group of inventions relates to transfusion medicine. Serums with thrombin are produced. For this purpose liquid blood sample is obtained, having first aliquot of liquid blood with procoagulant to make prothrombinaze enzyme complex associated with surface of procoagulant agent, which enables to obtain activated procoagulant agent, which can be stored. Activated procoagulant agent then may be subjected to interaction with second liquid blood aliquot containing prothrombin to obtain serum with Thrombin, which can be extracted and subjected to interaction with fibrinogen for preparing fibrin. To obtain serum with Thrombin special device is used containing reaction chamber with one or several compartments to hold procoagulant agent and liquid part of blood without flow. Procoagulant agent can reaction with said liquid part of blood to form fibrin gel, appliances to feed fluid into and from reaction chamber, means to retain solid particles in reaction chamber; agent for serum separation with Thrombin from fibrin gel. Further, device also comprises ventilation hole made with possibility of avoiding long period of staying under excessive pressure of reaction chamber. At that, one or several solid floating objects are present in reaction chamber, wherein solid loose objects, have diameter within range of 50 mcm and 2 mm, and other solid loose objects are characterised by dimensions selected for grinding of fibrin gel, and in cross section have, at least 4 mm.EFFECT: group of inventions allows eliminating risk of toxic reaction in patient in response to introduction of serum with Thrombin, risk of immunogenic reactions and risk of infectious diseases transmission from donors.25 cl, 8 dwg, 2 tbl

Preparation for prevention and treatment of diarrhoea in calves // 2583555
FIELD: veterinary science.SUBSTANCE: invention can be used for prevention and treatment of diarrhoea in calves. That is ensured by preparation containing hyperimmune polyvalent blood serum against diarrhoea with antibody titre of 1:300-1:600 in effective amount of sodium hypochlorite solution concentrated 300-350 mg/l at ratio of ingredients, wt%: serum: sodium hypochlorite 70:30-60:40, preserving agent, wherein preserving agent used is sodium hypochlorite solution in concentration of 700-750 mg/l in amount of 10-11 % of preparation.EFFECT: invention reduces cost of preparation and improves environmental safety of use while maintaining high efficiency and absence of side effects.1 cl, 4 tbl
ethod for soft tissue augmentation by means of heat-processed platelet-rich autoplasma // 2582948
FIELD: medicine.SUBSTANCE: method for face and/or neck soft tissue augmentation involving venous blood sampling in an amount of 9-36 ml; thereafter, the blood is centrifuged with acceleration of 1000 G for 5 minutes; the produced platelet-rich autoplasma is taken from the test tube in an amount of 3.0 ml by means of luer-lock syringes. The syringes containing the platelet-rich autoplasma are placed into a thermostat and kept there to produce gel. To introduce into a periorbital and neck region, the platelet-rich autoplasma is kept at 45°C for 5 minutes, or at 85°C for 6 minutes if it is necessary to introduce it into the other face regions. The produced gel is cooled down in a sterile tray for 2 minutes. By means of a connector, the syringe with the produced gel is attached to an empty sterile syringe; the produced gel is transited from one syringe into the other through 5-10 passages and introduced into the face region, avoiding the periorbital region, by means of a short-bevel needle 21G×3.8 cm. Before introduced into the periorbital and/or neck region, the produced gel of the platelet-rich autoplasma is mixed with untreated and platelet non-enriched autoplasma taken from the same patient, in ratio 2:1 and introduced into the periorbital and/or neck tissues by means of a short-bevel needle 27G×13 mm.EFFECT: method provides ensuring the uniform distribution and adequate correction of the desired regions.3 cl, 1 ex

ethod of treating acute anal fissure and persistent wounds of anal canal // 2578853
FIELD: medicine.SUBSTANCE: in treating acute anal fissure is auto plasma bubbling with increased content of platelets by ozone-oxygen mixture. Transferred by heating it in gel form, is introduced under anal crack in amount of 2.5-3.0 ml.EFFECT: method improves the anal fissure epithelization and postoperative rehabilitation due to prolonged therapeutic effect, minimum operation.1 cl, 1 ex, 4 dwg

ethod of treatment of osteoarthrosis of animals // 2565413
FIELD: veterinary science.SUBSTANCE: method includes effecting of the affected joint by enriched with platelets autoplazma, prepared 15-20 minutes before procedure by taking of 10-15 ml of autoblood, its one-stage centrifugation at the speed 1000 rpm within 10 minutes, with preparation of 0.5-1 ml of autoplazma enriched with platelets with concentration of platelets from 1000 to 1200 thousand/mcl, activation of the prepared autoplazma by 10% CaCl2 solution in the ratio 1:10. Autoplazma is injected into a joint cavity at the angle 90°. The number of procedures per course of treatment amounts 3-4 injections with the interval 7-10 days.EFFECT: method is highly effective for treatment of animals with osteoarthrosis of knee and other joints.5 dwg, 2 ex

ethod for producing agent possessing cytostatic action on human lymphoblasts // 2563170
FIELD: medicine.SUBSTANCE: method for producing an agent possessing cytostatic action on human lymphoblasts, wherein chicken blood sampling is preceded by electrical stimulation of chickens' heads at 100-120 V, 3-5 A, for 3-5 seconds; that is followed by sampling and incubating the blood, recovering serum and peptide fraction from the serum at molecular weight 850-1200 Da to be lyophilised and sterilised by exposing in a linear electron accelerator in a dose of 28-32 kGy.EFFECT: method enables producing an agent, which effectively suppresses malignant cells in acute lymphocytic leukaemia in the patient's body, reduces haematological and immunological toxicity and a risk of severe complications observed in anti-cancer chemotherapy.3 dwg, 2 tbl

ethod of obtaining, at least, one compound from blood and device for extraction for application in realisation thereof // 2560843
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to the pharmaceutical industry, in particular to a method of division of blood into fractions. The method of dividing blood into fractions consists in the division of blood into the fractions with the application of an extraction device of a certain construction under certain conditions. The extraction device for the division of blood fractions contains a body (1); the first needle (2) and the second needle (4), placed in selective flowing communication, where the said first needle (2) projects from the body (1); a switching device (3) for opening and closing flowing communication between the said needles (2, 4) and a button (3a) for bringing the said switching device (3) in action.EFFECT: method makes it possible to divide blood into fractions without mixing the said fractions.16 cl, 4 dwg, 5 ex

ethod of treating acute anal fissure // 2558995
FIELD: medicine.SUBSTANCE: treating acute anal fissure involves introducing autoplasma in an amount of 2-2.5 ml under the fissure. That is preceded by 5-minute autoplasma barbotage with ozone-oxygen mixture.EFFECT: method provides epithelising the anal fissure with minimum intraoperative injuries.3 dwg, 1 ex
ethod of obtaining fibrinogen concentrate // 2556804
FIELD: chemistry.SUBSTANCE: invention relates to biotechnology of obtaining haemostatic medications. Claimed is method of separating purified fibrinogen concentrate, free of viruses and ballast proteins. Solubilisation of cryoprecipitate of fresh frozen human plasma is realised. Fibrinogen is precipitated with 20-30% PEG solution. Separated sediment is dissolved in buffer with sodium citrate and sodium chloride. Virus inactivation of solution by solvent-detergent method is carried out in presence of 1-3% Tween-80 and 0.1-1.5% of tri-n-butylphoshate. Obtained concentrate is purified from products of virus inactivation and solvent-detergents by triple extraction with liquid paraffin. After that, obtained fibrinogen concentrate is re-precipitated with 1.0-2.5 M glycine solution. Sterile filtration and lyophilic drying with further corking of lyophilisate under vacuum and thermal inactivation are performed.EFFECT: invention makes it possible to obtained lyophilised form of fibrinogen concentrate with approximately 55% output.

Activated leukocyte composition // 2548741
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions refers to medicine and concerns a method for making an activated leukocyte composition involving human leukocyte incubation, exposure to hypotonic shock and addition of physiologically acceptable saline in an amount sufficient for the reconstitution of isotonicity, to the leukocytes. The group of inventions also concerns using: the activated leukocyte composition in preparing a drug for wound healing; a wound healing dressing containing the above composition.EFFECT: group of inventions provides preparing the composition containing a 90 times increase of the leukocyte count as compared to the known state-of-the-art methods.16 cl, 3 dwg, 6 tbl, 3 ex
ethod of treating bullous keratopathy // 2544306
FIELD: medicine.SUBSTANCE: invention refers to medicine, particularly to ophthalmopathy, and can be used in treating endothelial-epithelial corneal dystrophy. That is ensured by de-epithelisation, 12-o'clock corneal incision and splitting, administration of a biologically active substance into a stromal pocket of the cornea. The biologically active substance is poludan-activated autoplasma. Before the epithelisation is completed, a soft contact lens is placed on the cornea. The operation is followed by instillations of ciprofloxacin, diclofenac 6 times a day and infusions of cornegel.EFFECT: method provides reducing the intraoperative injuries and the length of patients' treatment, including by local (intrastromal) autocytokinotherapy.2 ex
ethod of treating trophic ulcers // 2543344
FIELD: medicine.SUBSTANCE: treating trophic ulcers is ensured by using autoserum prepared of blood 20.0-25.0 ml; centrifuging and separating it from a protein-thrombocyte clot are followed by edge chipping under a wound bed, while the protein-thrombocyte clot is used to be laid on the wound directly. The above procedures are repeated up to 20 times every two days.EFFECT: invention enables providing fast wound healing with the adequate recovery of the dermal skin layer by using the high-biocompatibility material containing the ingredients creating the optimum medium for the wound regeneration.2 ex
ethod for prevention of diffuse intra- and postoperative blood loss in surgery of abdominal aorta // 2540923
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to cardiovascular surgery, and concerns preventing a diffuse intra- and postoperative blood loss in surgery of abdominal aorta. To this effect, performing the aortoiliac operations is combined with measuring preoperative antithrombin III; if the measured value is less than 87±3%, a thromboelastography is performed from the moment of an anaesthetic support started with determining a coagulation index. If the coagulation index is less than 2.89±0.25 as early as at the start of the stage of approaching the abdominal aorta, before any surgically significant blood loss, fresh-frozen plasma of the identical group in a min. amount of 600 ml is administered into the patient. If the following dynamic control shows a decrease of the coagulation index below 1.10±0.28, at least 600 ml of fresh-frozen plasma is additionally administered, providing thereby the coagulation index by the end of the operation not less than 0.52±0.27.EFFECT: method provides effective prevention of intra- and postoperative blood loss by prevention of intraoperative homeostatic disorders.
ethod for conservative management of plantar fasciitis // 2531946
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to traumatology and orthopaedics, and aims at conservative treatment of plantar fasciitis. That is ensured by administering platelet rich autoplasma in an amount of 2.0 ml for each injection into an attachment point of the plantar aponeurosis to the calcaneum (the heel sac), inner and outer side surfaces of a midfoot, as well as to a plantar surface of the midfoot. The autoplasma is prepared 1-2 hours before the procedure, and it contains from 1243 thousand/mcl to 3029 thousand/mcl platelets. The normal autoplasma contains from 162 thousand/mcl to 358 thousand/mcl platelets. The autoplasma is activated with 0.25% CaCl2 in a ratio of 2:1 with added 5% sodium hydrocarbonate in a ratio of 1:20 to the prepared platelet rich plasma.EFFECT: above method enables providing pain management, recovering the extremity function, ensuring the stable clinical effect, and preventing complications.2 ex
ethod for recovering estrual cycling and fertility in cows suffering from hypo-ovarionism // 2531939
FIELD: medicine.SUBSTANCE: declared invention refers to veterinary science and aims at recovering the estrual cycling and fertility in cows suffering from hypo-ovarionism. The method involves single parenteral administration of the gonadotrophic preparation of a pregnant mare serum gonadotropin - folligon in a dose of 1,000 IU on the 7th day from the beginning of treatment with underlying pre-injections of 2.5% progesterone in a dose of 4 ml, on the 1st, 3rd and 5th days of the therapeutic course, 2% Sinestrol in a dose of 2 ml on the 1st and 3rd days, and Eleovit in a dose of 5 ml on the 1st and 7th day of treatment.EFFECT: declared invention provides normalising the hormonal-metabolic status and the recovered functional ovarian activity in the cows.2 tbl, 2 ex
ethod of treating ulcerous pyloroduodenal stenosis // 2527336
FIELD: medicine.SUBSTANCE: invention refers to medicine and can be used for treating ulcerous pyloroduodenal stenosis. That is ensured by single injections of patient's platelet rich plasma into a gastric mucosa on the periphery of scar tissues of a pyloric canal all around uniformly into 6 points in a dose of 0.2 ml. Then the stenotic area is exposed to ionised argon plasma for 5-8 days in a mode of unipolar spray coagulation at a power of 30 W, an argon flow of 1.5 litres a minute for 5-6 seconds; the number of exposures per one session makes 3 to 5.EFFECT: invention provides more effective non-invasive treatment of pyloroduodenal stenosis and reduces a length of treatment.2 ex
Pharmaceutical composition and method for preparing antiviral fractions (antivirus-c) // 2526799
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions refers to medicine and aims at cell protection against the cytopathogenic action of hepatitis C virus. What is declared is a pharmaceutical composition possessing antiviral action on hepatitis C virus and a method for preparing it. The chicken broiler's head is electrically stimulated in a mode of 100-120 V 3-4 A for 3-4 s. The blood is sampled and incubated at 4-8°C for 18-24 hours. The serum is sampled. The sampled serum is filtered through a filter of a pore size of 10 nm, lyophilised and irradiated in a line electron accelerator (LEA) in a mode of 10-40 kGy.EFFECT: using the declared group of inventions is effective for cell protection against the cytopathogenic action of hepatitis C virus.2 cl, 2 tbl, 1 ex
ethod of industrial production of fibrin-monomer from blood plasma // 2522237
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to the pharmaceutical industry, namely to a method of industrial production of fibrin-monomer from the blood plasma. The method of industrial production of fibrin-monomer from the blood plasma consists in defrosting fresh frozen human plasma with continuous mixing, with further addition into plasma of a saturated ammonium sulphate solution, the obtained mixture is kept at a temperature, after which it is centrifuged, a supernatant liquid is poured out; after that, urea is dissolved in a phosphate buffer and heated, with further dissolution in the buffer of the earlier obtained fibrinogen sediment, then, human thrombin is added and mixed; the mixture is kept at a room temperature, further, the obtained mixture is divided into three parts, the phosphate buffer is introduced into a reservoir with one of the three parts of the initial fibrinogen solution, a fibrin clot, formed in the reservoir is collected, washed in distilled water and pressed, as a result, three washed fibrin clots are obtained, after that, washing of the fibrin clot is repeated two more times in the same way, the final product - fibrin-monomer is obtained by dissolution of the washed fibrin clot in an acetate buffer with urea, the obtained fibrin-monomer is poured into flasks, after that, flasks with fibrin-monomer are frozen and freeze-dried under specified conditions.EFFECT: method makes it possible to increase the output of fibrin-monomer.2 ex

ethod for bone defect plasty // 2517563
FIELD: medicine.SUBSTANCE: what is applied is a stocking coating of an autogenous bone with a patient's platelet-rich plasma. Bone marrow aspirate from the patient's ilium and/or mesenchymal stromal cell autoculture prepared of the aspirate by culturing in vitro are injected under the coating layer into the autogenous bones. The autogenous bones are placed tightly in the bone defect to cover the defect area with adjacent soft tissues.EFFECT: complete and effective synthesis of the bone tissue continuity by creating conditions of proliferative process isolation and osteoresorption process deceleration in the autogenous bone with no undesired immunological responses in the plasty area.1 dwg, 1 ex

ethod of treating diseases requiring stimulation of immunity and repair processes // 2517060
FIELD: medicine.SUBSTANCE: with underlying conventional treatment, a leukocyte serum preparation is used that is produced by incubation of 20-30 ml of a patient's whole blood bottled in three sealed flasks in a thermostat at a temperature of 37-38°C for 24, 48 and 66-68 hours respectively; then the flasks are removed from the thermostat; the leukocyte serum is aspirated by a sterile syringe; the leukocyte serum preparation prepared at different times is introduced into the patient three times subcutaneously in a dose of 2-5 ml daily or triduan.EFFECT: method provides higher clinical effectiveness and reduced length of treatment.2 tbl, 1 ex
ethod for surgical treatment of ununited fractures and false joints of cylindrical bones in shortage of soft tissue in projection of ununited fractures and false joints // 2515146
FIELD: chemistry.SUBSTANCE: invention relates to medicine and specifically to trauma surgery and orthopaedics, and can be sued for surgical treatment of ununited fractures and false joints of cylindrical bones when there is a shortage of soft tissue. The method involves, 5-6 days before an operation, performing needle biopsy of bone and soft tissue fragments from the damage centre of the cylindrical bone and determining presence and nature of obligate intracellular viral infection (OIVI). Super-selective angiographic analysis of the microvascular channel to the capillary link is also performed. Valtrex is administered to the patient 2-4 days before the operation in a dose of 500 mg twice a day. Further, the method involves performing osteosynthesis or re-osteosynthesis with resection of the ends of bone fragments, opening marrowy canals, bone stimulation and batting the space of the bone defect with a gel-like nanostructured composite implant. In the presence of OIVI, resection of bone fragments is carried out in a larger volume until the onset of "pinpoint bleeding", i.e. to areas with satisfactory intrabone blood supply. The composite implant contains thrombocyte-rich autoplasma, mixed in ratio of 1:(1-2) with granules of a complex alloplastic preparation (CAP) based on hydroxyapatite which contains 50-60 wt % collagen. The composite implant also contains either 0.08-2.8 wt % colloidal solution of nanoparticles of zero-valent silver metal Ag0, or gold Au0, or copper Cu0, or palladium Pd0, or platinum Pt0, or 5-12 wt % nanoparticles of said metals in dry form. The nanoparticles have size of 2-40 nm. A colloidal solution of said nanoparticles or colloidal nanoparticles of said metals in dry form is added to the CAP granules. Further, the prepared granules of the gel-like complex alloplastic preparation are laid in a selected ratio on the layer of thrombocyte-rich autoplasma, without mixing, for subsequent transfer into the bone defect space. In case of performing resection of bone fragments in a larger volume until the onset of "pinpoint bleeding", corticotomy is further performed on the cylindrical bone being operated on, with subsequent distraction of the bone regenerate using any existing method. Further, the bone fragments are repositioned, followed by metallo-osteosynthesis. Before wound suturing, the surface of the area with shortage of soft tissue in the projection of the ununited fracture and false joints is covered by a semi-permeable flexible plate made of the complex alloplastic preparation based on hydroxyapatite, which contains 50-60 wt % collagen. The plate has thickness of 0.25-1.2 mm. The surface area of the plate is 10-20% greater than the area with shortage of soft tissue in the corresponding projection. The part of the erythrocyte mass remaining from preparing the thrombocyte-rich autoplasma and the plasma are returned into the bloodstream of the patient by intravenously using a drip during the surgical procedure or in the early post-operation period. After the operation, valtrex is administered to the patient in a dose of 500 gm once a day for two weeks and then in a dose of 500 mg every other day for two weeks.EFFECT: method provides reliable prevention of OIVI at a damage centre, normalisation of local microcirculation of blood, avoiding ischemic processes, and compensation for the shortening of the length of the limb of the patient being operated on while preventing weakening of the process of reparative osteogenesis and allergic reactions of the body.6 cl, 4 ex
ethod of treating erectile dysfunction // 2514639
FIELD: medicine.SUBSTANCE: common procedure is used to prepare platelet rich plasma to be administered at three stages. At the first stage, the platelet rich plasma is injected using an insulin syringe along a lateral surface of a penis in a bilateral direction: the autoplasma 1.0 ml is injected in a proximal, medial and distal direction; totally the autoplasma 3.0 ml is injected into each cavernous body. At the second stage, the autoplasma 2.0 ml is injected under an albugineous coat of the penis under ultrasonic control. The third stage involves injecting the autoplasma into sciatic-cavernous muscles 1.0 ml each with the penis slightly massaged to distribute the autoplasma. The procedure is repeated for three times every 1 week. The method enables stimulating the growth and development of the cavernous vessels promoting its revascularisation, improves the penis innervation, as well as enhances the functional capacities of the endothelium. The higher tone of the sciatic-cavernous muscles promotes better venous-occlusive component.EFFECT: regular spontaneous sleeping erections, improved morning erections, higher quality of patient's sex life.1 cl, 1 ex

ethod for normalising reproductive function // 2508117
FIELD: medicine.SUBSTANCE: invention refers to medicine and can be used for normalising (improving, recovering, stimulating) the mammalian, especially human, reproductive function. That involves the oral administration of a preparation representing high-lactate milk whey (HLMW) that contains 7% of dry substances, including 5% of milk whey and 2% of sodium hydroxide, or ammonium carbonate, or calcium hydroxide prepared by hydrolysis of milk whey pasteurised at temperature 53-57°C in the culture environment of Lactobacillus acidophilum and Lactobacillus bulgaricum at culture temperature 36 to 40°C and neutralisation of formed lactic acid with sodium hydroxide, or ammonium carbonate, or calcium hydroxide to achieve a weight fraction of lactose no more than 0.2%.EFFECT: method enables normalising the reproductive function, as well as its usage provides increasing the specific and non-specific body resistance and improving the erythropoiesis.4 cl, 7 tbl
ethod of preventing purulent-inflammatory complications in treatment of trauma-orthopedic patients with application of apparatuses of external fixation // 2508062
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to traumatology and orthopedics, and can be used for prevention of purulent-inflammatory complications from application of apparatuses of external fixation in the process of treatment of patients in traumatology and orthopedics. For this purpose transosseous osteosynthesis of long tubular bones is performed by introduction of wires and intraosseous rods of compression-distraction apparatus of external fixation into their proximal and distal fragments. Antimicrobial substance is applied on the surface of wires and intraosseous rods before their introduction into proximal and distal fragments, as well as on degreased surface of patient's skin in places of entrance and exit of wires and intraosseous rods. As antimicrobial means used is gel-like nanostructured composite implant. It is replaced on degreased surface of skin in places of entrance and exit of wires and intraosseous rods 2-4 weeks after initial application. Composite implant includes platelet-enriched autoplasma, mixed in ratio 1:1.0-2.0 with granules of complex alloplastic preparation on the basis of hydroxyapatite, which contains 50-60 wt % of collagen. Said complex alloplastic preparation additionally contains 0.08-2.8 wt % of colloid solution of zerovalent metal silver Ag0, or gold Au0, or copper Cu0, or palladium Pd0, or platinum Pt0, which is introduced into its granules at preparation stage. Size of introduced colloid zerovalent metal nanoparticles constitutes from 2 nm to 40 nm.EFFECT: method ensures efficient prevention of purulent-inflammatory complications in such patients due to elimination of microbial risk of bacterial contaminations in treatment of patients by means of apparatuses of external fixation.5 cl, 5 ex
Iimmunomodulator // 2504371
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmaceutical industry, namely to an immunomodulator. An immunomodulator for the immunocorrection accompanying the integrated treatment of chronic non-specific pulmonary diseases, chronic obstructive pulmonary disease, bronchial obstruction syndrome, chronic bronchial pneumonia, pulmonary fibrosis, tracheobronchitis, chronic laryngitis, pulmonary, tracheal and pharyngeal cancer; the immunomodulator is prepared by mixing a water infusion of rose bay leaves and a water infusion of yellow melilot taken in equal proportions, with a cattle lung and larynx powder, settling the prepared mixture, keeping on a boiling water bath, cooling; further, the mixture is filtered; the prepared solution is added with cattle blood serum containing leukaemia oncovirus antibodies, hemlock infusion, ascorbic and sorbic acids until all the ingredients fully dissolved; the prepared solution is placed in the water bath, cooled, filtered, sterilised under certain conditions.EFFECT: above preparation provides higher effectiveness and reduces the length of treating the above diseases, and ensures the higher immunobiological properties of the human body.3 ex
Dermatological agent // 2500409
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmacological and cosmetic industry, namely to a dermatological agent. The dermatological agent containing antler deer's dry blood plasma, Mumiyo, D-Panthenol, Sea buckthorn oil and additives in certain proportions.EFFECT: above dermatological agent possesses higher bioavailability and biological activity, as well as extends the range of similar products.2 cl

ethod of treating gastrointestinal diseases in calves // 2497531
FIELD: medicine.SUBSTANCE: declared invention refers to veterinary science, and aims at treating gastrointestinal diseases in calves. A method involves using the subcutaneous injections of convascelent's blood serum containing rota- and coronavirus antihemagglutinin in titres 1:128 and 1:64 respectively. The serum is introduced in a dose of 10.0 ml once a day for 9 days every 48 hours. That is combined with administering an infusion of a milled mixture of equal portions of purple Echinacea herb and blossom clusters (Echinazea purpurea), coltsfoot herb (Tussilago farfara), tillet blossom (Tilia cordata) and liquorice root (Glycyrrhiza glabra) prepared with the relation of the raw material to extractant that is 70% alcohol - 1:10 and kept at temperature 15-20°C for 7 days in the form of 7-8% aqueous solution in a dose of 3.5-4.5 ml/kg of animal's body weight every 12 hours to the clinical recovery.EFFECT: use of the declared invention provides the higher body resistance and faster recovery of the animal's body micro- and macroelement balance.5 tbl, 3 ex
Immunomodulator // 2497514
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to chemical-pharmaceutical industry, and represents an immunomodulator for treating chronic hepatitis, hepatic cancer, lymphatic sarcoma, chronic leukemia, and for improving the functions of liver and blood-forming organs, for enhancing the immunobiological body characteristics, prepared by mixing 1000 ml of an aqueous infusion of sandy everlasting blossom, pepper mint herb and chicory herb with 50 ml of bovine serum containing leukaemia oncovirus antibodies, 20 ml of wild rosemary infusion, 40 g of ascorbic acid, 2 g of sorbic acid, 0.2 g of folic acid until the ingredients are dissolved completely, with adding 60 g of liver powder, 30 g of lymphatic node powder, 30 g of young bovine spleen powder; the prepared solution is settled at room temperature for 24 hours, then kept at a boiling water bath for 30 minutes and cooled for 6-8 hours at room temperature; the settled solution is filtered, wherein the aqueous herbal solution is prepared by mixing equal proportions of the separately prepared aqueous infusions of 40 g of pepper mint herb in 1000 ml of water, 30 g of sandy everlasting blossom in 1000 ml of water and 30 g of chicory herb in 1000 ml of water, while the wild rosemary infusion is prepared by infusing 60 g of ground wild rosemary blossom in 1000 ml of 70% purified ethanol.EFFECT: invention provides creating the high-efficacy agent and reducing the length of treatment.
ethod of conservative treatment of shoulder epicondylitis // 2491964
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely, to traumatology and orthopedics, and can be applied in conservative treatment of shoulder epicondylitis. For this purpose rich of platelets autoplasma, obtained 1-2 hours before procedure, which contains from 725 to 3029 thousand/mcl platelets, is introduced into the point of maximal painfulness of epicondyle and in tissues located near it. Plasma is activated by 0.25% solution of CaCl2 in ratio 2:1 with addition of 5% sodium hydrocarbonate in ratio 1:20. Introduction is realised in amount from 3 to 5 ml.EFFECT: method ensures reduction of pain syndrome, recovery of extremity function with obtaining stable clinic effect due to stimulation of metabolism and processes of remodulation in pathologically changed tissues by components of obtained autoplasma.2 ex
ethod and composition for tissue regeneration using stem or marrow cells // 2491076
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmaceutical industry, namely a blood polymer for the regeneration of injured tissue or defect osseous or chondral structures. The blood polymer for the regeneration of injured tissue or defect osseous or chondral structures containing: blood, blood plasma or thrombocyte concentrate, erythropoietin (EPO), stem cells or marrow cells, wherein the blood polymer is prepared by mixing the respective ingredients taken in the liquid state, and the polymerisation is ensured by a gelling material specified in calcium ions, thrombin, protamine, prothrombin, fibrin or the extra-cellular matrix ingredients of a biological nature. The method for the regeneration of injured tissue or defect osseous or chondral structures in an individual.EFFECT: polymer enables the faster and better regeneration of injured and defect tissues.8 cl, 12 ex

ethod for differentiated stimulation of tissue repair and regeneration accompanying intra-articular fractures of cotyloid cavity // 2487735
FIELD: medicine.SUBSTANCE: invention refers to experimental medicine and may be used to study the stimulation of the reparative processes in tissues of an involved joint. That is ensured by simulating the intra-articular fracture of the cotyloid cavity. The stimulation involves the restoration of anatomic relationships in the joint, the stabilisation thereof with an external fixation apparatus. Later, starting from the second postoperative day, a solution or a mixture of solutions is introduced drop-by-drop into the joint cavity for 3-5 days. Differentiating in the osteoblastic direction and forming a preferential bone fusion requires a mixture of officinal solutions of 40% glucose, 5% ascorbic acid, autologous blood plasma, taken in a volume ratio of 1:2:7 to be introduced. For the purpose of the fibroblast differentiation and formation of a preferential connective tissue fusion, a mixture of officinal solutions of 5% glucose and 5% ascorbic acid in the volume ratio 1:1 is introduced. Differentiating in the chondroblastic direction and forming a preferential cartilage fusion are ensured by introducing officinal 0.9% sodium chloride solution.EFFECT: method provides the targeted regulation of the reparative processes in tissues of the involved joint.3 dwg, 3 ex

Sensitin for erythrocytic diagnosticum for diagnosing malignant new growths, and method for preparing it // 2487362
FIELD: medicine.SUBSTANCE: what is presented is sensitin for an erythrocytic diagnosticum for diagnosing the presence of malignant new growths, representing a mixture of low-molecular protein compound fractions of molecular weight 3000-15000 D, recovered from blood serum of a pregnant mare during early pregnancy, exhibiting promoting activity on malignant cell proliferation. What is also presented is a method for preparing this sensitin of blood serum of pregnant mares.EFFECT: invention allows the high-reliability detection of the presence of the malignant growths in a patient and relatively fast examination of large populations to detect the individuals who may suffer malignant new growths.7 cl, 4 dwg, 12 tbl, 12 ex
ethod for preparing hemostatic product 'gelplastan' // 2485963
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to medical pharmacology and represents a method for preparing a hemostatic product, involving treatment of gelatin in distilled water, incubation, cooling, addition of blood plasma and an antibiotic to gelatin, mixing, cooling, hardening, washing of an end product in water at least twice, grinding, drying at temperature 90°-200°C, additional grinding and sterilisation of the target product; cooling preceding hardening is conducted in a cold room at temperature -3°--5°C for 2.5 hours; the hard mass is carved 2.0×2.0×2.0 cm. The hemostatic may be used to arrest parenchymal and capillary hemorrhages in surgical practice.EFFECT: invention provides reducing power consumption and enhancing work capacity with keeping the production process continuous.1 ex
ethod of treating trophic ulcers // 2484837
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely surgery, and may be used for treating trophic ulcers. That is ensured by preparing an autoplasma heparin preparation. Before coating with the precipitate, the ulcer surface is covered with proper cells of a dermal surface layer.EFFECT: invention enables treating effectively trophic ulcers in the patients suffering diabetes mellitus.1 ex

Anti-burn gel // 2481121
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmaceutical industry, namely an anti-burn gel. The anti-burn gel for external application containing chitosan, salicylic acid, a biological regulator recovered from a bovine blood serum and represented an acidic protein fraction within the range of pH<3.0 and water taken in the specific relation.EFFECT: formulation provides manifested healing activity.7 dwg, 9 ex
Ossiculoplasty technique // 2479276
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to otorhinolaryngology, and may be applicable for surgical management of the patients with an ossicular chain pathology. For this purpose, an ossiculoplasty involves graft fixation by a platelet enriched autoblood plasma bunch taken immediately before the operation That is followed by laser coagulation of the bunch.EFFECT: technique provides improved functional effect and simplified ossiculoplasty, eliminated allergic reactions, eliminated risk of graft rejection, reduced recurrences due to fixation of the repaired elements, reduced risk of dislocation thereof up to formation of the physiological fixation ensured by middle ear soft tissues regeneration.1 ex
ethod of separating haematopoietic stem cells // 2474610
FIELD: chemistry.SUBSTANCE: method of separating haematopoietic stem cells (HSC) is realised by indirect immunomagnetic separation using inactivated fetal bovine serum (FBS) in amount of 4% and ethylenediaminetetraacetic acid (EDTA) in amount of 0.5 mmol. 5% aqueous solution of an aqua-complex of titanium glycerosolvate (ATG) is added to the obtained composition in amount of 1% of the amount of the obtained composition. The invention can be used when culturing stem cells with subsequent use thereof in cell therapy.EFFECT: invention increases content of viable cells for the same total output of HSC.1 tbl
 
2551115.
Up!